Bayer and J&J last year showed their legacy blood thinner Xarelto could help post-surgery patients in tough-to-treat artery disease. Now, the partners have data...
Johnson & Johnson’s COVID-19 vaccine ran into a big setback in late March when U.S. officials paused the rollout to investigate rare blood clots. While that issue...
AstraZeneca's target window to apply for emergency use authorization of its troubled COVID-19 vaccine in the U.S. has passed. But the company still plans to seek...
In the global COVID-19 vaccine race, mRNA vaccines quickly got out to the front of the pack and two reached distribution in less than a year. But their quick success...
While the FDA weighs whether to resume its trial of AstraZeneca's COVID-19 vaccine, which triggered a clinical hold last week after a U.K. patient was hit...
With its trials and pricing set, Pfizer has pulled back the curtain on the long-range commercial strategy for its COVID-19 vaccine. During its earnings call Tuesday, execs...